Covered recipient · General Payments record
SUNIL SHIVARAM
Allopathic & Osteopathic Physicians Ophthalmology
General Payments · PY2018–2024
$3,969.86
- Reported across 105 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $403.10 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Alcon Laboratories Inc | $104.59 | 4 |
| ABBVIE INC. | $58.76 | 2 |
| Harrow Eye, LLC | $50.29 | 2 |
| Bausch & Lomb Americas Inc. | $36.42 | 2 |
| Nova Eye, Inc. | $34.71 | 1 |
| Astellas Pharma US Inc | $33.16 | 1 |
| RxSight Inc | $26.18 | 1 |
| Thea Pharma Inc. | $21.53 | 1 |
| Oyster Point Pharma, Inc. | $20.17 | 1 |
| Amgen Inc. | $17.29 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $29.53 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106089892 | CMS |
| ABBVIE INC. | $29.23 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106089894 | CMS |
| Alcon Vision LLC | $30.13 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110568386 | CMS |
| Alcon Vision LLC | $24.05 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110568382 | CMS |
| Alcon Vision LLC | $21.96 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110568380 | CMS |
| Alcon Vision LLC | $28.45 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110568384 | CMS |
| Amgen Inc. | $17.29 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116120969 | CMS |
| Astellas Pharma US Inc | $33.16 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139430246 | CMS |
| Bausch & Lomb Americas Inc. | $20.25 | 12/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140455218 | CMS |
| Bausch & Lomb Americas Inc. | $16.17 | 12/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140455220 | CMS |
| Harrow Eye, LLC | $28.29 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145615949 | CMS |
| Harrow Eye, LLC | $22.00 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145615953 | CMS |
| Nova Eye, Inc. | $34.71 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152400268 | CMS |
| Oyster Point Pharma, Inc. | $20.17 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147423651 | CMS |
| RxSight Inc | $26.18 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144228208 | CMS |
| Thea Pharma Inc. | $21.53 | 03/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1074544793 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.